Clinical Trial Protocol
Iranian Registry of Clinical Trials

17 Sep 2026

NBUVB versus minocycline in vitiligo stabiling in unstable vitiligo

Protocol summary

Summary

Vitiligo is a common pigmentary disorder with great cosmetic, psychological morbidity and an unpredictable course. Unstable vitiligo is one of the main challenges treatment. After determining the sample size cases are selected from the patients with unstable vitiligo. Patients were randomly divided into two groups, and each group underwent three months of treatment with Minocycline or NBUVB. NBUVB group received NBUVB therapy twice a week and Minocycline group received Minocycline 100 mg once a daily. Both groups also treated with folic acid 5 mg daily, triamcinolone cream for face, groin, axilla and genital areas and clobetasol cream for other areas. At the end of the study, data review and analysis with SPSS software.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2013122315246N2**
Registration date: **2014-01-10, 1392/10/20**
Registration timing: **registered_while_recruiting**

Last update:
Update count: **0**

Registration date

2014-01-10, 1392/10/20

Registrant information

Name

Kioumars Jamshidi

Name of organization / entity

Isfahan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 31 1777 2134

Email address

kioumars_jamshidi@med.mui.ac.ir

Recruitment status

Recruitment complete

Funding source

Isfahan University of Medical Sciences

Expected recruitment start date

2012-07-12, 1391/04/22

Expected recruitment end date

2014-01-18, 1392/10/28

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

NBUVB versus minocycline in vitiligo stabiling in unstable vitiligo

Public title

Comparison of therapeutic effects of minocycline versus light therapy in vitiligo treatment

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criterion: unstable Vitiligo with 20- 50% body surface area involvement. Exclusion criteria: age ≤ 8 years or ≥50 years old; pregnancy or intention to become pregnant; breastfeeding; other severe systemic diseases e.g. cardiovascular, renal and hepatic failure; segmental vitiligo; acral vitiligo taking any other vitiligo treatment; history of having taken any medication that could interact with minocycline within the previous 3 months; history of photo-mediated disorders such as systemic lupus erythematous and xeroderma pigmentosa (XP) etc; known hypersensitivity to the study medication.

Age

From **8 years** old to **50 years** old

Gender

Both

Phase
N/A
Groups that have been masked
No information
Sample size
Target sample size: **42**
Randomization (investigator's opinion)
Randomized
Randomization description
Blinding (investigator's opinion)
Single blinded
Blinding description
Placebo
Not used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Isfahanl University of medical science
Street address
Deputy of research of isfahan university of medical science, hezarjerib street, Isfahan
City
Isfahan
Postal code
Approval date
2012-07-11, 1391/04/21
Ethics committee reference number
391262

Health conditions studied

1

Description of health condition studied
vitiligo
ICD-10 code
L80
ICD-10 code description
vitiligo

Primary outcomes

1

Description
Vitiligo stability
Timepoint
0, 1st, 2nd, 3rd months
Method of measurement
Vitiligo disease activity score (VIDA)

Secondary outcomes

1

Description
Side effects of drug
Timepoint
End of first, second and third month of treatment
Method of measurement
Examination

Intervention groups

1

Description
group 1: capsule minocycline 100 mg daily for 3 months
Category
Treatment - Drugs

2

Description
Group 2: NBUVB twice per week with 311 nm Wavelength, irradiance 1800–2000 μ W/cm 2 for 3 months
Category
Treatment - Other

Recruitment centers

1

Recruitment center
Name of recruitment center
Alzahra hospital of dermatology clinic
Full name of responsible person
Hospital dermatology clinic of alzahra
Street address
dermatology group,Alzahra hospital,Isfahan
City
Isfahan

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Isfahan Medical University
Full name of responsible person
Dr. Ebrahim Esfandiari
Street address
Isfahan University of Medical Sciiences, Hezar jerib Avne
City
Isfahan
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Isfahan Medical University

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Isfahanl University of Medical Sciences

Full name of responsible person

Dr. Naser Zeinali

Position

Resident of dermatology/MD

Other areas of specialty/work

Street address

Dermatology department, Alzahra hospital- Isfahan

City

Isfahan

Postal code

Phone

+98 33 1274 1553

Fax

Email

pr.zeanali1969@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Isfahanl University of Medical Sciences

Full name of responsible person

Dr. Amirhosein Siadat

Position

Aassistant professor of dermatology

Other areas of specialty/work

Street address

Dermatology department-Alzahra hospital-Isfahan

City

Isfahan

Postal code

Phone

Fax

Email

Amirhossein1@yahoo.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Isfahanl University of Medical Sciences

Full name of responsible person

Dr. Kioumars Jamshidi

Position

MD/Resident of dermatology

Other areas of specialty/work

Street address

dermatology group-Alzahra hospital-Isfahan

City

Isfahan

Postal code

Phone

+98 31 1777 2134

Fax

+98 31 1777 2134

Email

kioumars_jamshidi@med.mui.ac.ir;
kioumars_jamshidi2009@yahoo.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty